| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Daniel Wintner Goodman last filed a Form 4 in May 2021, as Director at TNXP. Daniel Wintner Goodman's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 5,001 shares of TNXP. Net of sales, the TNXP filings show accumulation of 5,000 shares.
Daniel Wintner Goodman has 4 Form 4 filings on record from May 2019 to May 2021, all as Director at Tonix Pharmaceuticals (TNXP), 2019–2021.
The 4 reported transactions were 3 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $6K and no sales.
The only open-market purchase was 5,000 shares of TNXP at an average $1.12 on May 25, 2021, about $6K. Twelve months later TNXP was down 94%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 25, 2021 | TNXP Tonix Pharmaceuticals Holding Corp. | Director | Buy | 5,000 | $1.12 | $5,600.00 | +500,000% | -38.4% | -94.4% |